TY - JOUR
T1 - A novel mechanism of γ-irradiation-induced IL-6 production mediated by P2Y11 receptor in epidermal keratinocytes
AU - Ohsaki, Airi
AU - Miyano, Yuki
AU - Tanaka, Rei
AU - Tanuma, Sei ichi
AU - Kojima, Shuji
AU - Tsukimoto, Mitsutoshi
N1 - Funding Information:
We thank Prof. Naoko Ohtani (Department of Pathophysiology, Osaka City University Graduate School of Medicine, Japan) for her kind suggestions and support.
Publisher Copyright:
© 2018 The Pharmaceutical Society of Japan.
PY - 2018
Y1 - 2018
N2 - Skin inflammation is caused by excessive production of cytokines and chemokines in response to an external stimulus, such as radiation, but the mechanisms involved are not completely understood. Here, we report a novel mechanism of γ-irradiation-induced interleukin-6 (IL-6) production mediated by P2Y11 receptors in epidermal cells. After irradiation of HaCaT cells derived from human epidermal keratinocytes with 5Gy of γ-rays (137Cs: 0.78Gy/min), IL-6 production was unchanged at 24h after γ-irradiation, but was increased at 48h. IL-6 mRNA was increased at 30h, and IL-6 production was increased at 33h after irradiation. The production of IL-6 was sustained at least for 4d after irradiation. P2Y11 receptor antagonist NF157 inhibited IL-6 production in irradiated cells. Treatment with ATP, a ligand of P2Y11 receptor caused IL-6 production within 24h. ATP-induced IL-6 production was also suppressed by NF157. Extracellular ATP level was increased after irradiation. The p38 mitogen-activated protein kinase (MAPK) and nuclear factor-kappaB (NF-κB) signaling was involved in the production of IL-6 at the downstream of P2Y11 receptor activation. In addition, the cell cycle was arrested at the G2/M phase, and DNA repair foci were not disappeared at 48h after γ-irradiation. The protein level of histone methylation enzyme G9a, which inhibits IL-6 production, was decreased after γ-irradiation. In conclusion, we suggest that γ-irradiation induces sustained IL-6 production in HaCaT cells from 33h after irradiation, which is mediated through P2Y11 receptor-p38 MAPK-NF-κB signaling pathway and G9a degradation. This is a novel mechanism of cytokine production in γ-irradiated cells.
AB - Skin inflammation is caused by excessive production of cytokines and chemokines in response to an external stimulus, such as radiation, but the mechanisms involved are not completely understood. Here, we report a novel mechanism of γ-irradiation-induced interleukin-6 (IL-6) production mediated by P2Y11 receptors in epidermal cells. After irradiation of HaCaT cells derived from human epidermal keratinocytes with 5Gy of γ-rays (137Cs: 0.78Gy/min), IL-6 production was unchanged at 24h after γ-irradiation, but was increased at 48h. IL-6 mRNA was increased at 30h, and IL-6 production was increased at 33h after irradiation. The production of IL-6 was sustained at least for 4d after irradiation. P2Y11 receptor antagonist NF157 inhibited IL-6 production in irradiated cells. Treatment with ATP, a ligand of P2Y11 receptor caused IL-6 production within 24h. ATP-induced IL-6 production was also suppressed by NF157. Extracellular ATP level was increased after irradiation. The p38 mitogen-activated protein kinase (MAPK) and nuclear factor-kappaB (NF-κB) signaling was involved in the production of IL-6 at the downstream of P2Y11 receptor activation. In addition, the cell cycle was arrested at the G2/M phase, and DNA repair foci were not disappeared at 48h after γ-irradiation. The protein level of histone methylation enzyme G9a, which inhibits IL-6 production, was decreased after γ-irradiation. In conclusion, we suggest that γ-irradiation induces sustained IL-6 production in HaCaT cells from 33h after irradiation, which is mediated through P2Y11 receptor-p38 MAPK-NF-κB signaling pathway and G9a degradation. This is a novel mechanism of cytokine production in γ-irradiated cells.
KW - G9a
KW - Interleukin-6 (IL-6)
KW - Nuclear factor-kappaB (NF-κB)
KW - P2Y11 receptor
KW - P38 mitogen-activated protein kinase (MAPK)
KW - γ-irradiation
UR - https://www.scopus.com/pages/publications/85048028824
U2 - 10.1248/bpb.b18-00075
DO - 10.1248/bpb.b18-00075
M3 - Article
C2 - 29553088
AN - SCOPUS:85048028824
SN - 0918-6158
VL - 41
SP - 925
EP - 936
JO - Biological and Pharmaceutical Bulletin
JF - Biological and Pharmaceutical Bulletin
IS - 6
ER -